Ajanta Pharma reported robust financial results for FY26, with revenue reaching ₹5,453 crore and Profit After Tax (PAT) at ₹1,056 crore. The company showcased strong growth in key segments like Branded Generics and US Generics, maintaining healthy margins despite forex volatility.

Ajanta Pharma Delivers Robust FY26 Performance

Ajanta Pharma announced strong financial results for the fiscal year 2026, crossing significant milestones with consolidated revenue from operations reaching ₹5,453 crore, a 17% increase year-on-year. Profit After Tax (PAT) grew by 15% to ₹1,056 crore. Adjusted EBITDA stood at ₹1,498 crore, marking an 18% rise.

Reader Takeaway: Strong revenue and profit growth driven by key segments, but Asia business faces minor headwinds.

What just happened

Ajanta Pharma reported its financial results for FY2026, highlighting a 17% year-on-year growth in consolidated revenue to ₹5,453 crore and a 15% increase in PAT to ₹1,056 crore. Adjusted EBITDA grew 18% to ₹1,498 crore. The company maintained an Adjusted EBITDA margin of 27% and a PAT margin of 19%.

Why this matters

These results demonstrate Ajanta Pharma's consistent growth trajectory and operational efficiency. The strong performance in key markets like the US Generics (49% growth) and India (14% growth) indicates effective market penetration and product strategy. Maintaining healthy return ratios like RoNW at 25% and RoCE at 33% signals efficient capital utilization.

The backstory

The company has been focusing on expanding its product portfolio and geographical reach. Branded Generics contribute significantly (68%) to overall revenue. Investments in R&D (₹252 crore) and capital expenditure for manufacturing expansion (₹330 crore) are part of its long-term strategy to develop complex products and enhance production capabilities.

What changes now

With these results, Ajanta Pharma solidifies its market position and enters FY2027 with confidence. The company plans to continue its focus on new product launches, R&D investment, and field force expansion to sustain growth and margins. Investors can expect continued focus on expanding US filings and recovery in the Asian markets.

Risks to watch

The company noted a 1% decline in its Asia business due to supply chain disruptions in the Middle East. Forex volatility, evidenced by a mark-to-market hedge loss of ₹103 crore, remains a potential concern that could impact profitability.

Peer comparison

Ajanta Pharma's reported revenue growth of 17% and PAT growth of 15% for FY26 indicate strong performance relative to the broader Indian pharmaceutical market, which Ajanta Pharma's India business outperformed with 14% growth. Specific peer comparisons on profitability and segment-specific growth would require further data.

Context metrics (time-bound)

• Revenue: ₹5,453 crore (FY26) vs. ₹4,648 crore (FY25), +17%
• Adjusted EBITDA: ₹1,498 crore (FY26) vs. ₹1,268 crore (FY25), +18%
• PAT: ₹1,056 crore (FY26) vs. ₹920 crore (FY25), +15%
• US Generics Growth: 49% (FY26)
• India Growth: 14% (FY26)
• R&D Investment: ₹252 crore (FY26)
• Capex: ₹330 crore (FY26)
• Inventory Days: 63 days (FY26) vs. 72 days (FY25)

What to track next

Investors will be closely watching the recovery of the Asia business, the progress of new product filings in the US market, and the company's ability to manage forex fluctuations and geopolitical impacts. Continued R&D investment and manufacturing capacity expansion will also be key indicators.